Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment-Reference-Cited by-同舟云学术

Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment

Published:2015-03-05 Issue:8 Volume:56 Page:2309-2314
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Gora-Tybor Joanna,Medras Ewa,Calbecka Malgorzata,Kolkowska-Leśniak Agnieszka,Ponikowska-Szyba Edyta,Robak Tadeusz,Jamroziak Krzysztof

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2014.994205

Reference24 articles.

1. Chronic Myeloid Leukemia: A Historical Perspective

2. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

3. Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

4. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

5. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling;Molecular and Cellular Biochemistry;2024-07-15

2. Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network;Frontiers in Cardiovascular Medicine;2023-02-07

3. hyperlipidemia-post-initiation-of-nilotinib-among-chronic-myeloid-leukemia-patients-in-a-tertiary-hospital-of-malaysia;Malaysian Journal of Pharmacy;2022-06-01

4. Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund: a nationwide cohort study;Supportive Care in Cancer;2022-03-18

5. Non-thrombotic ischemic cerebrovascular events related to the use of tyrosine kinase inhibitors in patients with cancer: high-resolution magnetic resonance imaging findings;Precision and Future Medicine;2021-12-31